SCHEDULE: Soleus Capital Discloses 5.4% Stake in Palisade Bio

Soleus Capital Master Fund and affiliated entities have reported a 5.4% beneficial ownership stake in Palisade Bio, Inc. common stock.

Summary

• Soleus Capital Master Fund, L.P. and its affiliates have filed a Schedule 13G indicating beneficial ownership of 9,353,687 shares of Palisade Bio, Inc. common stock.
• This holding represents 5.4% of the company's total outstanding common stock, based on 173,579,670 shares outstanding as of May 7, 2026.
• The filing confirms that the shares were acquired for investment purposes and not to influence or change the control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; it is a standard regulatory disclosure of an existing investment position without signaling immediate strategic changes.

Positives

• Institutional investor interest from Soleus Capital suggests confidence in the company's long-term prospects.
• The filing provides transparency regarding the ownership structure of the reporting entities.

Negatives

• The disclosure of a 5.4% stake may lead to increased share price volatility if the market perceives this as a precursor to future activist involvement or potential exit strategies.

Risks

• The investment is subject to market fluctuations and the general risks associated with the biotechnology sector.
• The reporting persons disclaim beneficial ownership for purposes other than Section 13(d) compliance, which may complicate interpretations of their long-term strategic intent.

Future Outlook

The reporting persons state that the securities were not acquired for the purpose of changing or influencing the control of the issuer, indicating a passive investment stance.

Management Comments

• The reporting persons certify that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that institutional filings of this nature are standard in the biotech sector, where specialized funds often take significant positions in small-cap companies to capitalize on clinical trial milestones or strategic pivots.

Comparison to Industry Standards

• The filing follows standard SEC regulatory requirements for beneficial ownership disclosure (Schedule 13G) for passive investors.
• The 5.4% threshold is a common entry point for institutional investors in the small-cap biotech space.

Stakeholder Impact

• Shareholders may view the entry of an institutional investor as a validation of the company's current valuation or pipeline potential.

Next Steps

• The reporting persons will be required to file amendments to this Schedule 13G if there are material changes in their percentage of ownership.

Key Dates

Keywords

Palisade Bio, Soleus Capital, Schedule 13G, Institutional Ownership, Biotech, Common Stock